Pepaxti
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Melphalan flufenamide
- Made by
- Oncopeptides AB (publ)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.4).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Oncopeptides AB (publ) |
|---|---|
| Active substance | Melphalan flufenamide |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01AA10 · Cancer treatments and immune-system medicines |
| Authorised on | 2022-08-17 |
| Last updated by the regulator | 2025-01-13 |
| EMA product number | EMEA/H/C/005681 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).